Strath contains 61 vital substances, from which each body takes what it needs,” says David Pestalozzi. Thirty-five studies of varying influence have been carried out to date. See Research at www.bio-strath.ch
Part 2 Strath (Bio-Stath) Tonic
To read Part 1 published 10 August – scroll this page. Part 3 will be published 13 August:
Since 1964, the production plant for “Strath” has been based above Herrliberg. A staff of six looks after the manufacturing process today. The company’s product range includes herbal remedies . The key section of the plant, some of which is underground, is the fermentation chamber with its four chromium-plated steel vats, each holding 12,000 litres. The food supplement makes use of the ability of yeast cells to “digest” the extracts of some 50 herbs added to them and to make the essence of these herbs accessible to the human body. http://www.voiceamerica.com/episode/72190/swiss-herbal-tonic-strath-successfully-impacts-wellbeing-and-quality-of-life-in-cancer-patients
But the herbal yeast cells obtained in this way still have to undergo a fermentation process that causes them to “burst” and liquefy. The production process lasts for two months and all that is added at the end is malt extract, honey and a little orange juice.
The end product is totally stable and can be stored for five years, even after the bottle has been opened: Strath contains 61 vital substances, from which each body takes what it needs,” says David Pestalozzi. Thirty-five studies of varying influence have been carried out to date. See Research at www.bio-strath.chContinue reading “Navigating the Cancer Maze Grace Gawler Voice America-Strath Tonic immune health, quality of life and wellbeing for cancer patients”
On today’s edition of Navigating the Cancer Maze, Grace Gawler interviews Dr Horst Lindhoffer PhD about one of the most innovative and exciting cancer immunotherapy treatment breakthroughs in many years. Visit germancancertreatments.com for more information.
On Navigating the Cancer Maze – Cancer Immunotherapy – Ground-breaking treatment in Cancer Medicine Grace Gawler -August 2, 2013
“Destroying cancer stem cells means fighting cancer at its roots”, says Horst Lindhofer, CEO of TRION Pharma. “Catumaxomab’s efficacy against this particularly aggressive and resistant population of cancer cells further supports its therapeutic potential for the treatment of EpCAM-positive carcinomas.”
On today’s edition of Navigating the Cancer Maze, I interview Dr Horst Lindhoffer PhD about one of the most innovative and exciting cancer treatment breakthroughs in many years. We know that The human immune system is usually quite effective at identifying and eliminating abnormal cells.
Dr Horst Lindhofer
Cancer cells, however, can form tumors and spread throughout the body. Although chaotic in their behavior, cancer cells operate with high level intelligence to escape detection by our immune system’s control mechanisms. Often misunderstood, this is a fundamental principle in understanding how cancer cells behave and how immune recognition can be assisted. The new breakthrough cancer treatments capitalize on that information. It has been a long-standing vision of physicians and scientists to develop a treatment that can put the immune system back on track. TRION has achieved the goal with its trifunctional Triomab® antibodies. Listen to learn more or contact grace@germancancertreatments.com for further details.
Listen to this interview at: http://www.voiceamerica.com/episode/72038/cancer-immunotherapy-ground-breaking-treatment-in-cancer-medicine
Catumaxomab (Removab®) is presently the only approved therapeutic antibody targeting EpCAM, a surface antigen that is widely expressed in the most frequent forms of human cancer. On April 20th this year, Removab® received EU approval for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas. Removab® is the first product world-wide to receive a regulatory approval for this indication. With its trifunctional mode of action, Removab® represents a new generation of antibodies using the body’s own immune system to help fight the tumor cells.
EpCAM: EpCAM or epithelial cell adhesion molecule is a pan-epithelial differentiation antigen that is expressed on almost all carcinomas, such as breast, lung, colorectal, gastric, prostate and ovarian cancer. Catumaxomab (Removab®) is the only approved anti-EpCAM antibody available.
Triomab®: Trifunctional antibodies : Triomab® antibodies bind to cancer-specific surface antigens and recruit both T cells as well as accessory cells, such as macrophages, dendritic cells and natural killer cells, to the tumor site. As a result, they provide for a new quality of cancer cell killing, activating both arms of the immune system – the adaptive one with cytotoxic T cells as effectors and the innate one including accessory effector cells.
dendritic cell image
Triomab® antibodies are therefore very effective in destroying cancer cells and show a therapeutic effect at very low doses. Triomab® antibodies are a development of TRION Pharma GmbH Catumaxomab was invented by TRION Pharma and has been developed with Fresenius Biotech.
But the herbal yeast cells obtained in this way still have to undergo a fermentation process that causes them to “burst” and liquefy. The production process lasts for two months and all that is added at the end is malt extract, honey and a little orange juice.
